Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Continued lack of progress in SCLC

Nature Reviews Clinical Oncology volume 7, pages 77–78 (2010)Cite this article

Subjects

Chemotherapy options for patients with extensive-stage small-cell lung cancer (SCLC) are limited. A recent phase III trial assessed the combination of carboplatin and pemetrexed but this regimen produced inferior survival results compared with the standard carboplatin and etoposide regimen. The combination of carboplatin and etoposide remains the standard first-line chemotherapy option for the treatment of patients with extensive-stage SCLC.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Socinski, M. A. et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small cell lung cancer. J. Clin. Oncol. 24, 4840–4847 (2006).

    Article  CAS  PubMed  Google Scholar 

  2. Socinski, M. A. et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 27, 4787–4792 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Jett, J. R. et al. Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study [abstract]. J. Clin. Oncol. 26, a8066 (2008).

    Article  Google Scholar 

  4. Gronberg, B. H. et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 63, 88–93 (2009).

    Article  PubMed  Google Scholar 

  5. Jalal, S. et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J. Thorac. Oncol. 4, 93–96 (2009).

    Article  PubMed  Google Scholar 

  6. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85–91 (2002).

    Article  CAS  PubMed  Google Scholar 

  7. Lara, P. N. Jr et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27, 2530–2505 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Hanna, N. et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038–2043 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Inoue, A. et al. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann. Oncol. doi: 10.1093/annonc/mdp384.

    Article  PubMed  Google Scholar 

  10. Inoue, A. et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol. 26, 5401–5406 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid, Box 8056, St Louis, 63110, MO, USA

    Janakiraman Subramanian & Ramaswamy Govindan

Authors
  1. Janakiraman Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramaswamy Govindan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramaswamy Govindan.

Ethics declarations

Competing interests

Ramaswamy Govindan declares he is a consultant for Lilly Oncology. Janakiraman Subramanian declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Subramanian, J., Govindan, R. Continued lack of progress in SCLC. Nat Rev Clin Oncol 7, 77–78 (2010). https://doi.org/10.1038/nrclinonc.2009.223

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.223

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing